{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:46:50Z","timestamp":1782953210700,"version":"3.54.5"},"reference-count":41,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T00:00:00Z","timestamp":1667865600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2022,11,30]]},"DOI":"10.1080\/21645515.2022.2127983","type":"journal-article","created":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T23:25:42Z","timestamp":1667949942000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":18,"title":["Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain"],"prefix":"10.1080","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-9252","authenticated-orcid":false,"given":"Renata","family":"Linertov\u00e1","sequence":"first","affiliation":[{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria, Spain"},{"name":"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud (SESCS), Santa Cruz de Tenerife, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Madrid, Spain"},{"name":"Red Espa\u00f1ola de Agencias de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias y Prestaciones del Sistema Nacional de Salud (RedETS), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-8204","authenticated-orcid":false,"given":"Carmen","family":"Guirado-Fuentes","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Canaria Instituto de Investigaci\u00f3n Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria, Spain"},{"name":"Servicio de Evaluaci\u00f3n del Servicio Canario de Salud (SESCS), Santa Cruz de Tenerife, Spain"},{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Madrid, Spain"},{"name":"Red Espa\u00f1ola de Agencias de Evaluaci\u00f3n de Tecnolog\u00edas Sanitarias y Prestaciones del Sistema Nacional de Salud (RedETS), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9455-4869","authenticated-orcid":false,"given":"Javier","family":"Mar-Medina","sequence":"additional","affiliation":[{"name":"Red de Investigaci\u00f3n en Servicios de Salud en Enfermedades Cr\u00f3nicas (REDISSEC), Madrid, Spain"},{"name":"Basque Health Service (Osakidetza), Debagoiena Integrated Healthcare Organisation, Research Unit, Arrasate-Mondrag\u00f3n, Spain"},{"name":"Kronikgune Institute for Health Service Research, Barakaldo, Spain"},{"name":"Biodonostia Health Research Institute, Donostia-San Sebasti\u00e1n, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4494-1000","authenticated-orcid":false,"given":"Conor","family":"Teljeur","sequence":"additional","affiliation":[{"name":"Health Information and Quality Authority (HIQA), Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,8]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000193"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2017.08.006"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pky045"},{"key":"e_1_3_5_5_1","unstructured":"European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries : focus on boys people living with HIV and 9-valent HPV vaccine introduction. [Internet]. Stockholm; 2020. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/guidance-hpv-vaccination-eu-focus-boys-people-living-hiv-9vHPV-vaccine."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jech-2020-216305"},{"key":"e_1_3_5_7_1","first-page":"1","article-title":"Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain","volume":"5515","author":"De La Fuente J","year":"2019","unstructured":"De La Fuente J, Hernandez Aguado JJ, Mart\u00edn MS, Boix PR, Cedillo S, L\u00f3pez N. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain. Hum Vaccin Immunother. 2019;5515:1\u201313.","journal-title":"Hum Vaccin Immunother"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gaceta.2009.07.011"},{"key":"e_1_3_5_9_1","volume-title":"Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys","author":"Health Information and Quality Authority (HIQA)","year":"2018","unstructured":"Health Information and Quality Authority (HIQA). Health technology assessment (HTA) of extending the national immunisation schedule to include HPV vaccination of boys. Dublin: Health Information and Quality Authority; 2018."},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.07.096"},{"key":"e_1_3_5_11_1","volume-title":"Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting","author":"Jim\u00e9nez E","year":"2015","unstructured":"Jim\u00e9nez E, Torkilseng EB, Klemp M. Cost-effectiveness of HPV-vaccination of boys aged 12 in a Norwegian setting. Oslo: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2015."},{"key":"e_1_3_5_12_1","unstructured":"Bruni L Albero G Serrano B Mena M Collado JJ G\u00f3mez D Mu\u00f1oz J Bosch F and de Sanjos\u00e9 S. ICO\/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in Spain. Summary report 2021 Oct 22."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.07.025"},{"key":"e_1_3_5_14_1","volume-title":"Proyecciones de poblaci\u00f3n - \u00daltimos datos.","author":"Instituto Nacional de Estad\u00edstica (INE)","year":"2019","unstructured":"Instituto Nacional de Estad\u00edstica (INE). Proyecciones de poblaci\u00f3n - \u00daltimos datos.2019 [accessed 2019]. https:\/\/www.ine.es\/INEbase\/Demograf\u00edINEbase\/Demograf\u00edA y poblaci\u00f3n\/Cifras de poblaci\u00f3n y Censos demogr\u00e1ficos\/proyecciones de poblaci\u00f3n\/\u00daltimos datos."},{"key":"e_1_3_5_15_1","unstructured":"MSCBS. Cobertura de vacunaci\u00f3n de la primera y segunda dosis de VPH en mujeres. 2018 [accesssed 2019]. https:\/\/www.sanidad.gob.es\/en\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/calendario-y-coberturas\/coberturas\/docs\/Todas_las_tablas2018.pdf."},{"key":"e_1_3_5_16_1","volume-title":"Historical data from the national HPV vaccination program register.","author":"Australian Government Department of Health","year":"2019","unstructured":"Australian Government Department of Health. Historical data from the national HPV vaccination program register.2019 [accesssed 2019]. https:\/\/www.health.gov.au\/resources\/collections\/historical-data-from-the-national-hpv-vaccination-program-register."},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3736201"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603469"},{"issue":"15","key":"e_1_3_5_19_1","first-page":"401","article-title":"Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males","volume":"364","author":"Giuliano AR","unstructured":"Giuliano AR, Palefsky JM, Goldstone S, Moreira Jr ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. Erratum appears N Engl J Med. 2011 Apr 14;364(15):401\u201311.","journal-title":"Erratum appears N Engl J Med"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"e_1_3_5_21_1","unstructured":"Cabas\u00e9s Hita JM S\u00e1nchez Iriso E Ollo L\u00f3pez A Errea Rodr\u00edguez M. Encuesta Nacional de Salud. Espa\u00f1a 2011\/12. Calidad de vida relacionada con la salud en adultos: EQ-5D-5L [Internet]; 2014. https:\/\/www.msssi.gob.es\/estadEstudios\/estadisticas\/encuestaNacional\/encuestaNac2011\/informesMonograficos\/CVRS_adultos_EQ_5D_5L.pdf."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.4321\/S1135-57272020000100016"},{"key":"e_1_3_5_23_1","first-page":"1132","article-title":"Moving towards an organized cervical cancer screening: costs and impact","volume":"28","author":"Diaz M","year":"2018","unstructured":"Diaz M, Mori\u00f1a D, Rodr\u00edguez-Sal\u00e9s V, Ib\u00e1\u00f1ez R, Espin\u00e1s JA, de Sanjos\u00e9 S. Moving towards an organized cervical cancer screening: costs and impact. Eur J Public Health. 2018;28:1132\u201338.","journal-title":"Eur J Public Health"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ciresp.2017.01.001"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2018.02.001"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.19819"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1097\/LGT.0b013e318182cd89"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aprim.2017.05.017"},{"key":"e_1_3_5_29_1","unstructured":"Oblikue Consulting S. Base de datos de costes sanitarios y ratios coste-efectividad espa\u00f1oles: eSalud [Internet]. [accessed 2020 Dec 1]. http:\/\/www.oblikue.com\/bddcostes\/."},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/hec.3633"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70017-6"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2017.04.004"},{"key":"e_1_3_5_33_1","first-page":"1","volume-title":"JCVI interim statement on extending HPV vaccination to adolescent boys","author":"Joint Commitee on Vaccination and Immunisation","year":"2017","unstructured":"Joint Commitee on Vaccination and Immunisation. JCVI interim statement on extending HPV vaccination to adolescent boys. London: The Joint Committee on Vaccination and Immunisation; 2017. p. 1\u201321."},{"key":"e_1_3_5_34_1","volume-title":"Statement on HPV vaccination joint committee on vaccination and immunisation","author":"Joint Commitee on Vaccination and Immunisation","year":"2018","unstructured":"Joint Commitee on Vaccination and Immunisation. Statement on HPV vaccination joint committee on vaccination and immunisation. London: The Joint Committee on Vaccination and Immunisation; 2018."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-019-4108-y"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2019.07.010"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-018-0996-9"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100401"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12962-017-0073-8"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2016.1208087"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.087"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00453-8"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2022.2127983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:43:59Z","timestamp":1737049439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2022.2127983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,8]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11,30]]}},"alternative-id":["10.1080\/21645515.2022.2127983"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2022.2127983","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-07-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2127983"}}